The Pentose Phosphate Pathway in Cancer: Regulation and Therapeutic Opportunities
| dc.contributor.author | Ghanem, Noorhan | |
| dc.contributor.author | el-Baba, Chirine Omar | |
| dc.contributor.author | Araji, Khaled | |
| dc.contributor.author | El-Khoury, Riyad | |
| dc.contributor.author | Usta, Julnar A.R. | |
| dc.contributor.author | Darwiche, Nadine D. | |
| dc.contributor.department | Biochemistry and Molecular Genetics | |
| dc.contributor.department | Pathology and Laboratory Medicine | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:38:12Z | |
| dc.date.available | 2025-01-24T11:38:12Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Background: Tumorigenesis is associated with deregulation of nutritional requirements, intermediary metabolites production, and microenvironment interactions. Unlike their normal cell counterparts, tumor cells rely on aerobic glycolysis, through the Warburg effect. Summary: The pentose phosphate pathway (PPP) is a major glucose metabolic shunt that is upregulated in cancer cells. The PPP comprises an oxidative and a nonoxidative phase and is essential for nucleotide synthesis of rapidly dividing cells. The PPP also generates nicotinamide adenine dinucleotide phosphate, which is required for reductive metabolism and to counteract oxidative stress in tumor cells. This article reviews the regulation of the PPP and discusses inhibitors that target its main pathways. Key Message: Exploiting the metabolic vulnerability of the PPP offers potential novel therapeutic opportunities and improves patients' response to cancer therapy. © 2021 S. Karger AG, Basel. | |
| dc.identifier.doi | https://doi.org/10.1159/000519784 | |
| dc.identifier.eid | 2-s2.0-85120324168 | |
| dc.identifier.pmid | 34775382 | |
| dc.identifier.uri | http://hdl.handle.net/10938/29008 | |
| dc.language.iso | en | |
| dc.publisher | S. Karger AG | |
| dc.relation.ispartof | Chemotherapy | |
| dc.source | Scopus | |
| dc.subject | Cancer | |
| dc.subject | Metabolism | |
| dc.subject | Pentose phosphate pathway | |
| dc.subject | Glucose | |
| dc.subject | Glycolysis | |
| dc.subject | Humans | |
| dc.subject | Neoplasms | |
| dc.subject | Oxidative stress | |
| dc.subject | Tumor microenvironment | |
| dc.subject | Glucose regulated protein 78 | |
| dc.subject | Glucose transporter 4 | |
| dc.subject | Glutathione | |
| dc.subject | Microrna | |
| dc.subject | Nicotinamide adenine dinucleotide phosphate | |
| dc.subject | Phosphate | |
| dc.subject | Protein bcl 2 | |
| dc.subject | Protein kinase b | |
| dc.subject | Protein p53 | |
| dc.subject | Sirtuin 1 | |
| dc.subject | Acute lymphoblastic leukemia | |
| dc.subject | Angiogenesis | |
| dc.subject | Antineoplastic activity | |
| dc.subject | Apoptosis | |
| dc.subject | Atherosclerosis | |
| dc.subject | Breast hyperplasia | |
| dc.subject | Cancer growth | |
| dc.subject | Cancer prognosis | |
| dc.subject | Cancer resistance | |
| dc.subject | Carcinogenesis | |
| dc.subject | Cell cycle arrest | |
| dc.subject | Cell cycle progression | |
| dc.subject | Cell invasion | |
| dc.subject | Cell proliferation | |
| dc.subject | Cell survival | |
| dc.subject | Colorectal cancer | |
| dc.subject | Crystal structure | |
| dc.subject | Cytotoxicity | |
| dc.subject | Deregulation | |
| dc.subject | Dna damage | |
| dc.subject | Enzyme activity | |
| dc.subject | G1 phase cell cycle checkpoint | |
| dc.subject | Gene expression | |
| dc.subject | Genetic transcription | |
| dc.subject | Glucose 6 phosphate dehydrogenase deficiency | |
| dc.subject | Glucose tolerance | |
| dc.subject | Glucose transport | |
| dc.subject | Glycosylation | |
| dc.subject | Human | |
| dc.subject | Huntington chorea | |
| dc.subject | Hydrogen bond | |
| dc.subject | Ic50 | |
| dc.subject | Inflammation | |
| dc.subject | Liver cell carcinoma | |
| dc.subject | Lung adenocarcinoma | |
| dc.subject | Lung cancer | |
| dc.subject | Lymph node metastasis | |
| dc.subject | Malignant neoplasm | |
| dc.subject | Metabolic regulation | |
| dc.subject | Microenvironment | |
| dc.subject | Mitochondrial respiration | |
| dc.subject | Mouth cancer | |
| dc.subject | Nucleic acid metabolism | |
| dc.subject | Nucleotide metabolism | |
| dc.subject | Nutritional requirement | |
| dc.subject | Osteoarthritis | |
| dc.subject | Ovary cancer | |
| dc.subject | Oxidation | |
| dc.subject | Pancreas cancer | |
| dc.subject | Pentose phosphate cycle | |
| dc.subject | Pi3k/akt signaling | |
| dc.subject | Prostate cancer | |
| dc.subject | Protein synthesis | |
| dc.subject | Psoriasis | |
| dc.subject | Review | |
| dc.subject | Synthesis | |
| dc.subject | Thyroid cancer | |
| dc.subject | Thyroid papillary carcinoma | |
| dc.subject | Tumor growth | |
| dc.subject | Tumor invasion | |
| dc.subject | Tumor regression | |
| dc.subject | Tumor suppressor gene | |
| dc.subject | Tumor volume | |
| dc.subject | Unfolded protein response | |
| dc.subject | Upregulation | |
| dc.subject | Uterine cervix cancer | |
| dc.subject | Warburg effect | |
| dc.subject | Neoplasm | |
| dc.title | The Pentose Phosphate Pathway in Cancer: Regulation and Therapeutic Opportunities | |
| dc.type | Review |
Files
Original bundle
1 - 1 of 1